Drug intelligence / Profile preview

ECI-NPs

Development stage: Preclinical
Lead developer: Chengdu Public Health Clinical Center
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

**ECI-NPs** are an experimental carrier-free multifunctional nanoparticle system generated through oxidative coupling of epigallocatechin gallate oligomers, curcumin, and indocyanine green. The nano-integrated construct was reported by researchers at the Public Health Clinical Center of Chengdu and Sichuan University as an in vitro antitumor and antibacterial platform. It improves the stability, cellular uptake, and controlled release of its constituent active compounds and enhances light-mediated photodynamic and photothermal cytotoxicity in melanoma cells, while also showing antibacterial activity against *Escherichia coli* and *Staphylococcus aureus*. ECI-NPs have not been reported as a clinical-stage or marketed therapeutic product.

Other names: ECI-NPs

Targets

NF-κB

Beyond the preview

Go deeper on ECI-NPs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECI-NPs.

Explore the full profile